000 01249 a2200337 4500
005 20250517034004.0
264 0 _c20151016
008 201510s 0 0 eng d
022 _a1699-3993
024 7 _a10.1358/dot.2015.51.4.2291051
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aDahl, J
245 0 0 _aBlinatumomab for the treatment of adult acute lymphoblastic leukemia.
_h[electronic resource]
260 _bDrugs of today (Barcelona, Spain : 1998)
_cApr 2015
300 _a231-41 p.
_bdigital
500 _aPublication Type: Journal Article; Review
650 0 4 _aAdult
650 0 4 _aAntibodies, Bispecific
_xadministration & dosage
650 0 4 _aAntigens, CD19
_ximmunology
650 0 4 _aAntigens, Neoplasm
_ximmunology
650 0 4 _aAntineoplastic Agents
_xadministration & dosage
650 0 4 _aClinical Trials as Topic
650 0 4 _aDisease-Free Survival
650 0 4 _aHumans
650 0 4 _aPrecursor Cell Lymphoblastic Leukemia-Lymphoma
_xdrug therapy
700 1 _aMace, M
700 1 _aKantarjian, H
700 1 _aJabbour, E
773 0 _tDrugs of today (Barcelona, Spain : 1998)
_gvol. 51
_gno. 4
_gp. 231-41
856 4 0 _uhttps://doi.org/10.1358/dot.2015.51.4.2291051
_zAvailable from publisher's website
999 _c24942484
_d24942484